A randomized, double-blind, placebo-controlled crossover trial using valaciclovir to suppress HSV [herpes simplex virus] and HIV shedding in HIV-1, HSV-2 coinfected persons

Trial Profile

A randomized, double-blind, placebo-controlled crossover trial using valaciclovir to suppress HSV [herpes simplex virus] and HIV shedding in HIV-1, HSV-2 coinfected persons

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs Valaciclovir (Primary)
  • Indications Herpes simplex virus infections; HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2007 Status changed from in progress to completed.
    • 15 Sep 2006 Status change
    • 22 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top